Analysis of the Efficacy and Safety of Ultrasound-guided Pingyangmycin Combined with Microwave Ablation in the Treatment of Microcystic Lymphatic Malformations in Children
DOI:
https://doi.org/10.18063/apm.v10i2.898Keywords:
Microcystic lymphatic malformation, Microwave ablation, Pingyangmycin, Ultrasound-guided, Combined therapy, ChildrenAbstract
Objective: To evaluate the efficacy and safety of ultrasound-guided Pingyangmycin sclerotherapy combined with microwave ablation (MWA) for treating microcystic lymphatic malformations (LMs) in children, compared to Pingyangmycin sclerotherapy alone. Methods: This single-group study enrolled 108 pediatric patients with microcystic LM hospitalized between January 2022 and September 2023. Patients were divided into two groups based on treatment received: the Sclerotherapy group (n = 74, Pingyangmycin injection alone) and the Combination group (n = 34, Pingyangmycin injection followed by MWA). Baseline characteristics, lesion parameters (location, initial volume, intralesional fluid characteristics), treatment details (Pingyangmycin dosage, number of sessions), efficacy outcomes (Volume Reduction Rate [VRR], Efficacy Grade), and complications were recorded and statistically compared. Results: The Combination group had significantly larger initial lesion volumes (59.2 mL vs. 11.6 mL, p < 0.001) and were predominantly located in the lower limbs (76.5% vs. 29.7%), while the Sclerotherapy group lesions were mainly in the face & neck (33.8% vs. 2.9%). The Combination group used significantly less Pingyangmycin (median 0.5 mg vs. 2.0 mg, p < 0.001, a 75% reduction) and required fewer treatment sessions (88.2% vs. 47.3% completed in one session, p < 0.001). VRR was comparable between groups (Combination: 57.4% vs. Sclerotherapy: 52.0%, p = 0.344), as was the proportion achieving >75% reduction (Grade IV: 26.5% vs. 24.3%, p = 0.887). Overall complication rates were similar (p = 0.232), though mild pain incidence was higher in the Combination group (41.2% vs. 21.6%). Conclusion: Ultrasound-guided combined Pingyangmycin and MWA therapy significantly reduces Pingyangmycin dosage and treatment frequency while achieving comparable efficacy to sclerotherapy alone in pediatric microcystic LM. The dual chemical-thermal ablation mechanism offers a precise, minimally invasive option, particularly advantageous for craniofacial lesions. Larger, long-term studies are warranted to validate these findings.
References
Sun R, Tuchin V, Zharov V, et al., 2018, Current Status, Pitfalls and Future Directions in the Diagnosis and Therapy of Lymphatic Malformation. Journal of Biophotonics, 11(8): e201700124.
Itakura E, Yamamoto H, Oda Y, , 2009, VEGF-C and VEGFR-3 in a Series of Lymphangiomas: Is Superficial Lymphangioma a True Lymphangioma?. Virchows Archiv, 454(3): 317–325.
Elluru R, Balakrishnan K, Padua H, 2014, Lymphatic Malformations: Diagnosis and Management. Seminars in Pediatric Surgery, 23(4): 178–185.
Hathaway B, Radu S, Wilson J, et al., 2021, Lymphatic and Mixed Malformations. Lymphatic Research and Biology, 19(1): 41–50.
Mehl S, Kinley A, Todd H, et al., 2022, Institutional Management of Abdominal Lymphatic Malformations: Evolution of Treatment Over a Decade. The Journal of Surgical Research, 280: 296–303.
Madsen H, Annam A, Harned R, et al., 2019, Symptom Resolution and Volumetric Reduction of Abdominal Lymphatic Malformations With Sclerotherapy. The Journal of Surgical Research, 233: 256–261.
Candussi I, Petecariu A, Lungu M, et al., 2024, Giant Intraabdominal Lymphangioma in a Pediatric Patient—A Challenging Diagnosis. Clinics and Practice, 14(3): 739–748.
Özcan C, Vayisoglu Y, Güner N, et al., 2010, External Laryngopyocele: A Rare Cause of Upper Airway Obstruction. The Journal of Craniofacial Surgery, 21(6): 2022–2024.
Yang W, Wang H, Xie C, et al., 2024, Management for Lymphatic Malformations of Head and Neck. Frontiers in Neurology, 15: 1450102.
Wang Y, Seo H, Kim H, 2002, Sclerotherapy With OK-432 for the Treatment of Lymphangiomas. Cancer Research and Treatment, 34(1): 62–66.
Khurana A, Gupta A, Ahuja A, et al., 2018, Lymphangioma Circumscriptum Treated With Combination of Bleomycin Sclerotherapy and Radiofrequency Ablation. Journal of Cosmetic and Laser Therapy, 20(6): 326–329.
Elbaaly H, Piché N, Rypens F, et al., 2021, Intra-Abdominal Lymphatic Malformation Management in Light of the Updated International Society for the Study of Vascular Anomalies Classification. Pediatric Radiology, 51(5): 760–772.
Wu H, Wang X, Zheng J, et al., 2016, Treatment of Deep-Seated Facial Microcystic Lymphatic Malformations With Intralesional Injection of Pingyangmycin. Medicine, 95(37): e4790.
Perkins J, Manning S, Tempero R, et al., 2010, Lymphatic Malformations: Current Cellular and Clinical Investigations. Otolaryngology—Head and Neck Surgery, 142(6): 789–794.
Liu C, Qin Z, Fan Z, et al., 2012, New Treatment Strategy for Granulomatous Epulis: Intralesional Injection of Propranolol. Medical Hypotheses, 78(2): 327–329.
Wang H, Zhao W, Xu M, et al., 2021, Treatment of Keloids by Surgical Excision Combined With 5-Fluorouracil and Betamethasone Injection. Dermatologic Surgery, 47(5): 740–741.
Teng J, Hammill A, Martini J, et al., 2023, Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review. Lymphatic Research and Biology, 21(2): 101–110.
